AMLX — Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on NASDAQ. It is led by Joshua B. Cohen, based in 43 Thorndike Street, Cambridge, MA, United States, 02141, with about 123 employees. Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Latest reported AMLX revenue for 2025-09-30 was $0. Net income was -$111.7M. AMLX currently screens at market cap $561.6M.

Use this AMLX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AMLX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AMLX SEC filings page. Lician reads the product cache first so this HTML stays unique to Amylyx Pharmaceuticals Inc even when a live quote feed is slow.